Breaking: SkinCeuticals is launching a targeted skincare regimen to address potential side effects of GLP-1 weight loss drugs like Ozempic and Wegovy, anticipating a surge in demand as the market expands.The company’s new A.G.E. Interrupter Ultra serum is designed to combat skin laxity, a common concern among individuals experiencing rapid weight loss.
The growing popularity of GLP-1 receptor agonists – medications initially developed for type 2 diabetes but increasingly prescribed for weight loss – is creating a new opportunity within the skincare industry.Experts note that rapid weight loss can lead to decreased hydration and collagen production, resulting in looser skin and amplified fine lines and wrinkles. JP Morgan Research projects that 30 million Americans could be on a weight loss drug by 2030, fueling a demand for preventative and corrective skincare solutions.
SkinCeuticals, a brand owned by L’Oréal, is strategically positioning itself to capitalize on this trend. “We are laser-focused on medical trends driving consumers to clinics, and that’s how we got the idea to test this A.G.E. Interrupter Ultra Serum with GLP-1 patients,” said Tara pyle, SkinCeuticals’ general manager, in a recent interview. The company’s approach centers on combining scientific advancements in skincare with aesthetic procedures.
The accessibility of GLP-1s is expanding beyond conventional medical settings. Medical spas are increasingly offering thes medications, with weight loss services becoming a leading revenue driver for these establishments. Pyle noted that weight loss is frequently enough a “gateway to medical aesthetics involvement,” citing a McKinsey report indicating that 63 percent of GLP-1 patients pursue aesthetic procedures for the first time *after* starting weight loss medication. The American Society of Plastic Surgeons reports that 41 percent of patients prescribed GLP-1s are considering non-surgical cosmetic procedures.
Market research from Circana further supports this trend, showing that GLP-1 users demonstrate increased spending in beauty categories. SkinCeuticals conducted internal testing on 25 participants (both male and female) using a regimen including the A.G.E. Interrupter Advanced Cream and the new Ultra Serum. Results showed visible reductions in skin laxity within four weeks. Combining the regimen with a minimally invasive ultrasound procedure on GLP-1 patients yielded an additional 20 percent reduction in skin laxity.
The A.G.E. (Advanced Glycation End-products) Interrupter line focuses on preventing the formation of damaging glycation end products, which contribute to collagen breakdown and skin aging. The Ultra Serum is formulated with [specific ingredients not disclosed in original article,but typically include proxylane and blueberry extract] to target these processes.
SkinCeuticals plans to continue researching the impact of GLP-1s on skin health, recognizing the long-term potential of this market segment. “GLP-1s [are] not going anywhere. It is indeed a major segment of our medical customers, so it will always be a consideration,” Pyle stated. The company’s strategy reflects a broader industry trend of integrating skincare with medical weight loss treatments to address the holistic needs of patients.











